急性呼吸窘迫综合征住院患者使用阿托伐他汀对临床结局的影响  

Effect of atorvastatin on clinical outcomes in hospitalized patients with acute respiratory distress syndrome

作　　者：张凯旋 姚智远 廖兆敏 伍威[1] 江贵军 张召才[2] 宋振举 詹丽英[1] 夏文芳[1] ZHANG Kaixuan;YAO Zhiyuan;LIAO Zhaomin;WU Wei;JIANG Guijun;ZHANG Zhaocai;SONG Zhenju;ZHAN Liying;XIA Wenfang(Dept.of Critical Care Medicine,Renmin Hospital of Wuhan University,Wuhan 430060,Hubei,China;Dept.of Critical Care Medicine,The Second Affiliated Hospital,Zhejiang University School of Medicine&Zhejiang Province Clinical Research Center for Emergency and Critical Care Medicine,Hangzhou 310009,Zhejiang,China;Dept.of Emergency,Zhongshan Hospital Fudan University&Institute of Emergency Rescue and Critical Care,Fudan University,Shanghai 200032,China)

机构地区：[1]武汉大学人民医院重症医学科,湖北武汉430060 [2]浙江大学医学院附属第二医院重症医学科/浙江省急危重症临床医学研究中心,浙江杭州310009 [3]复旦大学附属中山医院急诊科/复旦大学应急救援与急危重症研究所,上海200032

出　　处：《武汉大学学报(医学版)》2025年第2期194-198,共5页Medical Journal of Wuhan University

基　　金：国家重点研发计划(编号:2021YFC2501800);国家自然科学基金(编号:82272226);武汉市知识创新专项项目(编号:2023020201010165);武汉大学人民医院交叉创新人才项目(编号:JCRCZN⁃2022⁃017);武汉大学研究生导师育人方式创新项目(编号:413200144)。

摘　　要：目的:探讨急性呼吸窘迫综合征(ARDS)住院患者使用阿托伐他汀对于炎症指标、凝血功能及预后的影响。方法:本研究采用回顾性队列研究,在武汉大学人民医院ARDS专病数据库中选取了256名入住ICU并且诊断为ARDS的患者,其中128名使用了阿托伐他汀治疗(阿托伐他汀组),128名未使用(对照组),观察阿托伐他汀用药前后患者炎症指标及凝血功能指标PT和APTT的变化,并且评估使用阿托伐他汀对患者预后的影响。结果:阿托伐他汀组28 d死亡率与对照组相比显著降低(P<0.05),无呼吸机天数和ICU住院时间无显著差异。阿托伐他汀组用药前后炎症指标无明显改善(P>0.05);PT和APTT延长(P<0.05)。结论:ARDS患者使用阿托伐他汀可改善凝血功能,并能降低其死亡率,提示阿托伐他汀可改善ARDS患者的临床结局,可作为ARDS患者的一种治疗选择。Objective:To investigate the impact of atorvastatin on inflammatory markers,coagulation func-tion,and prognosis in hospitalized patients with acute respiratory distress syndrome(ARDS).Methods:We conducted a retrospective cohort study using the ARDS-specific database from Renmin Hospital of Wuhan University.A total of 256 ICU patients diagnosed with ARDS were selected,in-clunding 128 patients who received atorvastatin treatment(atorvastatin group)and 128 did not(control group).Changes in inflammatory markers and coagulation function(PT and APTT)were observed be-fore and after atorvastatin administration and its impact on patient prognosis was assessed.Results:In the atorvastatin group,the 28-day mortality rate was significantly lower than that in the control group(P<0.05).However,there was no significant improvement in inflammatory markers after atorvas-tatin treatment(P>0.05);coagulation indices,PT,and APTT,in the atorvastatin group were pro-longed after treatment(P<0.05).Conclusion:The use of atorvastatin in ARDS patients can improve coagulation function and reduce mortality rates,suggesting that atorvastatin may improve clinical out-comes and could be considered a therapeutic option for ARDS patients.

关 键 词：阿托伐他汀 急性呼吸窘迫综合征 预后 凝血功能 炎症指标 

分 类 号：R563.9[医药卫生—呼吸系统]